Compare ORN & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORN | FHTX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 332.2M |
| IPO Year | 2007 | 2020 |
| Metric | ORN | FHTX |
|---|---|---|
| Price | $10.97 | $5.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $16.25 | $11.50 |
| AVG Volume (30 Days) | ★ 449.8K | 151.6K |
| Earning Date | 03-03-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 25.32 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $852,260,000.00 | $30,909,000.00 |
| Revenue This Year | $8.50 | $14.62 |
| Revenue Next Year | $7.83 | $15.27 |
| P/E Ratio | $172.17 | ★ N/A |
| Revenue Growth | 7.01 | ★ 36.75 |
| 52 Week Low | $4.64 | $2.94 |
| 52 Week High | $15.00 | $6.95 |
| Indicator | ORN | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 43.38 |
| Support Level | $8.18 | $4.47 |
| Resistance Level | $11.70 | $5.85 |
| Average True Range (ATR) | 0.83 | 0.37 |
| MACD | -0.14 | -0.05 |
| Stochastic Oscillator | 28.57 | 39.27 |
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.